SlideShare a Scribd company logo
1 of 9
AAV interactions with host-cell
receptor AAVR
MaLi Dong
Chapman Lab
QBB Engineering Internship Program
26 August 2015
Adeno-associated virus (AAV2)
• Single stranded DNA
• Not known to cause disease
• Enters host cell through receptor-
mediated endocytosis
• Has clinical success as recombinant DNA
in gene therapy
 Can infect without integrating into genome of
host cell Fig.1. 3D crystal structure of AAV2
centered on viral 5-fold axis1
1. Weisman, J, 2015. Surface of the AAV-2 serotype of the adeno-associated virus, with one of the five fold axes centered. Derived from the 3-A crystal structure,1LP3. Image.
Wikipedia (2015).
Adeno-associated virus receptor (AAVR)
• Direct binding
• Resistant mammalian cells to AAV2 infection
• Universal receptor
• E.coli as host cells for AAVR protein
• Express with His-tags to test with other receptors
 6 histidine residue
Gel electrophoresis
• Resulting test expressions
• Isopropyl β-D-1-
thiogalactopyranoside (IPTG)
• Little difference between 3 hour
and overnight induction
• 1-5 His-tag constructs were used
in electron microscopy
Sample preparation
Fig.2. 300 mesh copper grid Fig.3. Size comparison Fig.4. PELCO easiGlowTM
Tecnai iCorr
• Integrated light and electron
microscope
 Combines fluorescence light
microscope and electron
microscope
• Accelerates CLEM experiments
• High resolution EM images
sample
Grid 4
• AAV2 VLP –KL-His complex
in HN buffer
• 1/10 dilution
• Aggregated binding around
virus
• Imidazole to free His-
tagged proteins from Nickel
ions
Grid 6
• Same mix as Grid 4
• 1/100 dilution
• Aggregated binding around
virus
• Nanogold appears to be
binding
Thanks to
• Dr. Michael Chapman
• Dr. Qing Xie
• Dr. Omar Davulcu
• Nancy Meyer
• Andrew Trzynka
• Jazz Weisman

More Related Content

What's hot

The Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccines
The Immunobiology of Oil-in-Water Adjuvants for Influenza VaccinesThe Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccines
The Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccinespcirnkt
 
Sleep and the Gut Microbiome-bioRxiv-199075 1
Sleep and the Gut Microbiome-bioRxiv-199075 1Sleep and the Gut Microbiome-bioRxiv-199075 1
Sleep and the Gut Microbiome-bioRxiv-199075 1Jon Lendrum
 
Final Summer IBB poster
Final Summer IBB posterFinal Summer IBB poster
Final Summer IBB posterÁngel Garcés
 
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...Merial EMEA
 
Pertussis Aaar Talk
Pertussis Aaar TalkPertussis Aaar Talk
Pertussis Aaar Talkmccabekm
 
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...EuFMD
 
Better ways to predict effectors for functional characterization and resistan...
Better ways to predict effectors for functional characterization and resistan...Better ways to predict effectors for functional characterization and resistan...
Better ways to predict effectors for functional characterization and resistan...Kelsey Wood
 
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...Melina Mottin
 
Gene therapy-Best Ever
Gene therapy-Best EverGene therapy-Best Ever
Gene therapy-Best EverImdadulHaque
 
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...OS20 - Validation of recombinant protein-based ELISA for detection of antibod...
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...EuFMD
 
Detecting neutralization antibodies to covid 19
Detecting neutralization antibodies to covid 19Detecting neutralization antibodies to covid 19
Detecting neutralization antibodies to covid 19Melvin Alex
 
an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 antomathew8
 
mRNA-1273 (Moderna COVID vaccine)
mRNA-1273 (Moderna COVID vaccine)mRNA-1273 (Moderna COVID vaccine)
mRNA-1273 (Moderna COVID vaccine)Serena Hijazeen
 
Th1_Towards the identification of genetic factors that control resistance of ...
Th1_Towards the identification of genetic factors that control resistance of ...Th1_Towards the identification of genetic factors that control resistance of ...
Th1_Towards the identification of genetic factors that control resistance of ...Africa Rice Center (AfricaRice)
 

What's hot (20)

ADVANCES IN BREEDING FOR YVMV RESISTANCE IN OKRA
ADVANCES IN BREEDING FOR YVMV RESISTANCE IN OKRAADVANCES IN BREEDING FOR YVMV RESISTANCE IN OKRA
ADVANCES IN BREEDING FOR YVMV RESISTANCE IN OKRA
 
The Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccines
The Immunobiology of Oil-in-Water Adjuvants for Influenza VaccinesThe Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccines
The Immunobiology of Oil-in-Water Adjuvants for Influenza Vaccines
 
Sleep and the Gut Microbiome-bioRxiv-199075 1
Sleep and the Gut Microbiome-bioRxiv-199075 1Sleep and the Gut Microbiome-bioRxiv-199075 1
Sleep and the Gut Microbiome-bioRxiv-199075 1
 
Final Summer IBB poster
Final Summer IBB posterFinal Summer IBB poster
Final Summer IBB poster
 
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...
Ipvs2014 02 mortensen et al.-pcv2 circulation control in danish fatteners abs...
 
Pertussis Aaar Talk
Pertussis Aaar TalkPertussis Aaar Talk
Pertussis Aaar Talk
 
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...
OS20 - Exploring foot-and-mouth disease virus antibody affinity using bio-lay...
 
Better ways to predict effectors for functional characterization and resistan...
Better ways to predict effectors for functional characterization and resistan...Better ways to predict effectors for functional characterization and resistan...
Better ways to predict effectors for functional characterization and resistan...
 
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...
Opening the Discovery of New Antiviral Candidates Against Zika Virus and Insi...
 
Gene therapy-Best Ever
Gene therapy-Best EverGene therapy-Best Ever
Gene therapy-Best Ever
 
The Necessary
The NecessaryThe Necessary
The Necessary
 
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...OS20 - Validation of recombinant protein-based ELISA for detection of antibod...
OS20 - Validation of recombinant protein-based ELISA for detection of antibod...
 
Muldoon.B poster final
Muldoon.B poster finalMuldoon.B poster final
Muldoon.B poster final
 
Detecting neutralization antibodies to covid 19
Detecting neutralization antibodies to covid 19Detecting neutralization antibodies to covid 19
Detecting neutralization antibodies to covid 19
 
an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2 an mrna vaccine aganist sars cov 2
an mrna vaccine aganist sars cov 2
 
mRNA-1273 (Moderna COVID vaccine)
mRNA-1273 (Moderna COVID vaccine)mRNA-1273 (Moderna COVID vaccine)
mRNA-1273 (Moderna COVID vaccine)
 
Th1_Towards the identification of genetic factors that control resistance of ...
Th1_Towards the identification of genetic factors that control resistance of ...Th1_Towards the identification of genetic factors that control resistance of ...
Th1_Towards the identification of genetic factors that control resistance of ...
 
Lary nel abao genetic engineering final report
Lary nel abao genetic engineering final reportLary nel abao genetic engineering final report
Lary nel abao genetic engineering final report
 
DNA
DNADNA
DNA
 
Saurabh verma (2)
Saurabh verma (2)Saurabh verma (2)
Saurabh verma (2)
 

Similar to QBB Engineering Internship Program final presentation

Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approaches
Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approachesDr. Tanja Opriessnig - Update on novel experimental pig vaccine approaches
Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approachesJohn Blue
 
kurt cyto 2015_Ks final
kurt cyto 2015_Ks finalkurt cyto 2015_Ks final
kurt cyto 2015_Ks finalDr Kurt Sales
 
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhD
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhDSIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhD
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhDMars Stone
 
STDS- recent diagnosis methods@1223.pptx
STDS- recent diagnosis methods@1223.pptxSTDS- recent diagnosis methods@1223.pptx
STDS- recent diagnosis methods@1223.pptxKamalJungShahi
 
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014St John's Laboratory Ltd
 
Gene Replacement Therapy .pptx
Gene Replacement Therapy .pptxGene Replacement Therapy .pptx
Gene Replacement Therapy .pptxantil380
 
Dr9 biosafetyhandlingforgenereplacementtherapydc01 r
Dr9 biosafetyhandlingforgenereplacementtherapydc01 rDr9 biosafetyhandlingforgenereplacementtherapydc01 r
Dr9 biosafetyhandlingforgenereplacementtherapydc01 rMiomir Knežević
 
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxDR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxAliElmehdawi2
 
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxDR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxJoySalinday
 
Antiretroviral therapy failure
Antiretroviral therapy failureAntiretroviral therapy failure
Antiretroviral therapy failureParvez Pathan
 
HIV Therapeutic vaccines
HIV Therapeutic vaccinesHIV Therapeutic vaccines
HIV Therapeutic vaccinesreza mozafari
 
Viral vectors Gene Replacement Therapy.pptx
Viral vectors Gene Replacement Therapy.pptxViral vectors Gene Replacement Therapy.pptx
Viral vectors Gene Replacement Therapy.pptxBinteHawah1
 
Deshpande et al. Retrovirology (2016)
Deshpande et al. Retrovirology (2016)Deshpande et al. Retrovirology (2016)
Deshpande et al. Retrovirology (2016)SHILPA PATIL
 
Vaccine efficacy of FMD virus -like particles like particles like particles ...
 Vaccine efficacy of FMD virus -like particles like particles like particles ... Vaccine efficacy of FMD virus -like particles like particles like particles ...
Vaccine efficacy of FMD virus -like particles like particles like particles ...EuFMD
 
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...EuFMD
 
Molvis 0810-publish[1]
Molvis 0810-publish[1]Molvis 0810-publish[1]
Molvis 0810-publish[1]doc30845
 
how immunity generated from covid 19 vaccines differs from
how immunity generated from covid 19 vaccines differs fromhow immunity generated from covid 19 vaccines differs from
how immunity generated from covid 19 vaccines differs fromDr-Ajay Tripathi
 

Similar to QBB Engineering Internship Program final presentation (20)

Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approaches
Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approachesDr. Tanja Opriessnig - Update on novel experimental pig vaccine approaches
Dr. Tanja Opriessnig - Update on novel experimental pig vaccine approaches
 
kurt cyto 2015_Ks final
kurt cyto 2015_Ks finalkurt cyto 2015_Ks final
kurt cyto 2015_Ks final
 
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhD
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhDSIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhD
SIV Viral Variation; Implications for Vaccines and Transmission - Mars Stone PhD
 
STDS- recent diagnosis methods@1223.pptx
STDS- recent diagnosis methods@1223.pptxSTDS- recent diagnosis methods@1223.pptx
STDS- recent diagnosis methods@1223.pptx
 
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014Presentation of David Rimm in 1st International Antibody Validation Forum 2014
Presentation of David Rimm in 1st International Antibody Validation Forum 2014
 
Gene Replacement Therapy .pptx
Gene Replacement Therapy .pptxGene Replacement Therapy .pptx
Gene Replacement Therapy .pptx
 
Dr9 biosafetyhandlingforgenereplacementtherapydc01 r
Dr9 biosafetyhandlingforgenereplacementtherapydc01 rDr9 biosafetyhandlingforgenereplacementtherapydc01 r
Dr9 biosafetyhandlingforgenereplacementtherapydc01 r
 
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxDR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
 
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptxDR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
DR9BiosafetyHandlingforGeneReplacementTherapyDC01-R.pptx
 
PMED Opening Workshop - Beyond ART: Towards Eradication or Drug-Free Control ...
PMED Opening Workshop - Beyond ART: Towards Eradication or Drug-Free Control ...PMED Opening Workshop - Beyond ART: Towards Eradication or Drug-Free Control ...
PMED Opening Workshop - Beyond ART: Towards Eradication or Drug-Free Control ...
 
Antiretroviral therapy failure
Antiretroviral therapy failureAntiretroviral therapy failure
Antiretroviral therapy failure
 
HIV Therapeutic vaccines
HIV Therapeutic vaccinesHIV Therapeutic vaccines
HIV Therapeutic vaccines
 
Viral vectors Gene Replacement Therapy.pptx
Viral vectors Gene Replacement Therapy.pptxViral vectors Gene Replacement Therapy.pptx
Viral vectors Gene Replacement Therapy.pptx
 
Lab diagnosis hiv
Lab diagnosis hivLab diagnosis hiv
Lab diagnosis hiv
 
Deshpande et al. Retrovirology (2016)
Deshpande et al. Retrovirology (2016)Deshpande et al. Retrovirology (2016)
Deshpande et al. Retrovirology (2016)
 
Deshpande et al.,Retrovirology 2016
Deshpande et al.,Retrovirology 2016Deshpande et al.,Retrovirology 2016
Deshpande et al.,Retrovirology 2016
 
Vaccine efficacy of FMD virus -like particles like particles like particles ...
 Vaccine efficacy of FMD virus -like particles like particles like particles ... Vaccine efficacy of FMD virus -like particles like particles like particles ...
Vaccine efficacy of FMD virus -like particles like particles like particles ...
 
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...
OS18 - 7.2 Vaccine Efficacy (vaccine efficacy of FMD virus-like particles pro...
 
Molvis 0810-publish[1]
Molvis 0810-publish[1]Molvis 0810-publish[1]
Molvis 0810-publish[1]
 
how immunity generated from covid 19 vaccines differs from
how immunity generated from covid 19 vaccines differs fromhow immunity generated from covid 19 vaccines differs from
how immunity generated from covid 19 vaccines differs from
 

QBB Engineering Internship Program final presentation

  • 1. AAV interactions with host-cell receptor AAVR MaLi Dong Chapman Lab QBB Engineering Internship Program 26 August 2015
  • 2. Adeno-associated virus (AAV2) • Single stranded DNA • Not known to cause disease • Enters host cell through receptor- mediated endocytosis • Has clinical success as recombinant DNA in gene therapy  Can infect without integrating into genome of host cell Fig.1. 3D crystal structure of AAV2 centered on viral 5-fold axis1 1. Weisman, J, 2015. Surface of the AAV-2 serotype of the adeno-associated virus, with one of the five fold axes centered. Derived from the 3-A crystal structure,1LP3. Image. Wikipedia (2015).
  • 3. Adeno-associated virus receptor (AAVR) • Direct binding • Resistant mammalian cells to AAV2 infection • Universal receptor • E.coli as host cells for AAVR protein • Express with His-tags to test with other receptors  6 histidine residue
  • 4. Gel electrophoresis • Resulting test expressions • Isopropyl β-D-1- thiogalactopyranoside (IPTG) • Little difference between 3 hour and overnight induction • 1-5 His-tag constructs were used in electron microscopy
  • 5. Sample preparation Fig.2. 300 mesh copper grid Fig.3. Size comparison Fig.4. PELCO easiGlowTM
  • 6. Tecnai iCorr • Integrated light and electron microscope  Combines fluorescence light microscope and electron microscope • Accelerates CLEM experiments • High resolution EM images sample
  • 7. Grid 4 • AAV2 VLP –KL-His complex in HN buffer • 1/10 dilution • Aggregated binding around virus • Imidazole to free His- tagged proteins from Nickel ions
  • 8. Grid 6 • Same mix as Grid 4 • 1/100 dilution • Aggregated binding around virus • Nanogold appears to be binding
  • 9. Thanks to • Dr. Michael Chapman • Dr. Qing Xie • Dr. Omar Davulcu • Nancy Meyer • Andrew Trzynka • Jazz Weisman